

Ming Yao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8585056/publications.pdf>

Version: 2024-02-01

135
papers

6,847
citations

76196

40
h-index

62479

80
g-index

137
all docs

137
docs citations

137
times ranked

10078
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. <i>Biomaterials</i> , 2007, 28, 2959-2966.	5.7	561
2	Bifunctional Magnetic Silica Nanoparticles for Highly Efficient Human Stem Cell Labeling. <i>Nano Letters</i> , 2007, 7, 149-154.	4.5	486
3	AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. <i>Blood</i> , 2009, 114, 5352-5361.	0.6	318
4	The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. <i>Biomaterials</i> , 2009, 30, 3645-3651.	5.7	305
5	TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. <i>Blood</i> , 2011, 118, 3803-3810.	0.6	272
6	Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. <i>Hepatology</i> , 2014, 59, 2092-2100.	3.6	235
7	DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. <i>Blood</i> , 2012, 119, 559-568.	0.6	211
8	Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells. <i>Clinical Cancer Research</i> , 2005, 11, 1372-1379.	3.2	202
9	Mesoporous Silica Nanoparticles as a Delivery System of Gadolinium for Effective Human Stem Cell Tracking. <i>Small</i> , 2008, 4, 1445-1452.	5.2	201
10	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. <i>Blood</i> , 2010, 115, 2749-2754.	0.6	193
11	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. <i>Blood</i> , 2010, 116, 4086-4094.	0.6	187
12	Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. <i>Cancer</i> , 2004, 100, 366-375.	2.0	185
13	Nucleophosmin Mutations in De novo Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. <i>Cancer Research</i> , 2006, 66, 3310-3316.	0.4	165
14	WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. <i>Blood</i> , 2010, 115, 5222-5231.	0.6	156
15	The inhibitory effect of superparamagnetic iron oxide nanoparticle (Ferucarbotran) on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells. <i>Toxicology and Applied Pharmacology</i> , 2010, 245, 272-279.	1.3	147
16	Mesoporous Silica Nanoparticles Improve Magnetic Labeling Efficiency in Human Stem Cells. <i>Small</i> , 2008, 4, 619-626.	5.2	128
17	The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. <i>Blood</i> , 2012, 120, 3106-3111.	0.6	127
18	<i>RUNX1</i> gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. <i>British Journal of Haematology</i> , 2007, 139, 405-414.	1.2	122

#	ARTICLE	IF	CITATIONS
19	Internalization of mesoporous silica nanoparticles induces transient but not sufficient osteogenic signals in human mesenchymal stem cells. <i>Toxicology and Applied Pharmacology</i> , 2008, 231, 208-215.	1.3	122
20	SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2003, 37, 300-305.	1.5	108
21	Epidemiology of multiple myeloma in Taiwan. <i>Cancer</i> , 2007, 110, 896-905.	2.0	92
22	Splicing factor mutations predict poor prognosis in patients with <i>de novo</i> acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 9084-9101.	0.8	77
23	<i>IDH</i> mutations are closely associated with mutations of <i>DNMT3A</i> , <i>ASXL1</i> and <i>SRSF2</i> in patients with myelodysplastic syndromes and are stable during disease evolution. <i>American Journal of Hematology</i> , 2014, 89, 137-144.	2.0	76
24	Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. <i>Journal of Hepatology</i> , 2018, 69, 286-292.	1.8	76
25	Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. <i>Blood</i> , 2009, 113, 3161-3167.	0.6	75
26	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. <i>Blood Cancer Journal</i> , 2018, 8, 39.	2.8	68
27	In vivo magnetic resonance imaging of cell tropism, trafficking mechanism, and therapeutic impact of human mesenchymal stem cells in a murine glioma model. <i>Biomaterials</i> , 2011, 32, 3275-3284.	5.7	58
28	Intracranial hemorrhage in adult patients with hematological malignancies. <i>BMC Medicine</i> , 2012, 10, 97.	2.3	58
29	Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. <i>Blood</i> , 2013, 121, 3172-3180.	0.6	58
30	Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. <i>American Journal of Hematology</i> , 2013, 88, E277-82.	2.0	56
31	Clinical implications of the <i>SETBP1</i> mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. <i>American Journal of Hematology</i> , 2014, 89, 181-186.	2.0	56
32	Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 904-912.	0.4	55
33	Expression of cereblon protein assessed by immunohistochemical staining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. <i>Annals of Hematology</i> , 2014, 93, 1371-1380.	0.8	54
34	Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. <i>EBioMedicine</i> , 2018, 37, 91-100.	2.7	54
35	Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson's disease. <i>Nanoscale</i> , 2018, 10, 2998-3007.	2.8	53
36	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. <i>Annals of Hematology</i> , 2020, 99, 501-511.	0.8	52

#	ARTICLE	IF	CITATIONS
37	High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. PLoS ONE, 2015, 10, e0128410.	1.1	50
38	Clinical and Microbiological Characteristics of Perianal Infections in Adult Patients with Acute Leukemia. PLoS ONE, 2013, 8, e60624.	1.1	48
39	Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer, 2015, 15, 344.	1.1	48
40	Iron Oxide Nanoparticle-Induced Epidermal Growth Factor Receptor Expression in Human Stem Cells for Tumor Therapy. ACS Nano, 2011, 5, 9807-9816.	7.3	43
41	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2019, 19, 617.	1.1	43
42	Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008–2013. International Journal of Antimicrobial Agents, 2017, 49, 272-281.	1.1	41
43	Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. Journal of Hematology and Oncology, 2021, 14, 25.	6.9	41
44	Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. Blood Cancer Journal, 2017, 7, 663.	2.8	39
45	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clinical Epigenetics, 2018, 10, 42.	1.8	36
46	<i>SF3B1</i> mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution. American Journal of Hematology, 2014, 89, E109-15.	2.0	34
47	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. Blood Cancer Journal, 2018, 8, 87.	2.8	34
48	Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. Journal of the Formosan Medical Association, 2004, 103, 526-32.	0.8	34
49	Clinical implications of SOCS1 methylation in myelodysplastic syndrome. British Journal of Haematology, 2006, 135, 317-323.	1.2	32
50	Homologous RBC-derived vesicles as ultras-small carriers of iron oxide for magnetic resonance imaging of stem cells. Nanotechnology, 2010, 21, 235103.	1.3	32
51	Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review. Medical Mycology, 2011, 49, 1-7.	0.3	31
52	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in <i>de novo</i> acute myeloid leukemia patients. European Journal of Haematology, 2018, 101, 86-94.	1.1	31
53	Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Advances, 2021, 5, 2456-2466.	2.5	31
54	Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001–2010. International Journal of Antimicrobial Agents, 2012, 40, 533-538.	1.1	30

#	ARTICLE	IF	CITATIONS
55	Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma. <i>Oncotarget</i> , 2016, 7, 62490-62502.	0.8	30
56	Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i> . <i>Haematologica</i> , 2018, 103, e510-e513.	1.7	29
57	Clinical features of patients with infections caused by <i>Candida guilliermondii</i> and <i>Candida fermentati</i> and antifungal susceptibility of the isolates at a medical centre in Taiwan, 2001-10. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2632-2635.	1.3	24
58	GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution. <i>Annals of Hematology</i> , 2015, 94, 211-221.	0.8	23
59	Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. <i>EBioMedicine</i> , 2019, 40, 240-250.	2.7	23
60	Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. <i>Leukemia Research</i> , 2014, 38, 1278-1284.	0.4	22
61	MR Findings of Intrathecal Chemotherapy-Related Myelopathy in Two Cases: Mimicker of Subacute Combined Degeneration. <i>Journal of Neuroimaging</i> , 2007, 17, 184-187.	1.0	21
62	Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation. <i>Blood</i> , 2011, 118, 1340-1349.	0.6	21
63	High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0126037.	1.1	21
64	Clinical characteristics and treatment outcomes of patients with candidaemia due to <i>Candida parapsilosis sensu lato</i> species at a medical centre in Taiwan, 2000-12. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1531-1538.	1.3	21
65	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). <i>Oncotarget</i> , 2016, 7, 63177-63188.	0.8	21
66	Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. <i>BMC Gastroenterology</i> , 2018, 18, 6.	0.8	20
67	RBC-derived vesicles as a systemic delivery system of doxorubicin for lysosomal-mitochondrial axis-improved cancer therapy. <i>Journal of Advanced Research</i> , 2021, 30, 185-196.	4.4	20
68	Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation. <i>Scientific Reports</i> , 2016, 6, 36730.	1.6	18
69	Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 1420-1424.	1.7	17
70	Simultaneous determination of triazole antifungal drugs in human plasma by sweeping-micellar electrokinetic chromatography. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 404, 217-228.	1.9	17
71	IPSS in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. <i>American Journal of Hematology</i> , 2014, 89, E142-9.	2.0	16
72	Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. <i>Annals of Hematology</i> , 2003, 82, 558-564.	0.8	15

#	ARTICLE	IF	CITATIONS
73	Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence—clinical implication and comparison between the West and the East. <i>Annals of Hematology</i> , 2013, 92, 799-806.	0.8	14
74	Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation. <i>Clinical and Experimental Ophthalmology</i> , 2018, 46, 698-700.	1.3	14
75	The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression. <i>Haematologica</i> , 2014, 99, 1799-1807.	1.7	13
76	2016 guideline strategies for the use of antifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2018, 51, 287-301.	1.5	13
77	Dextran-coated iron oxide nanoparticles turn protumor mesenchymal stem cells (MSCs) into antitumor MSCs. <i>RSC Advances</i> , 2016, 6, 45553-45561.	1.7	12
78	Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma. <i>Journal of Radiation Research</i> , 2017, 58, 114-122.	0.8	12
79	The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan. <i>Annals of Hematology</i> , 2019, 98, 745-752.	0.8	12
80	Orbital and ocular adnexal lymphoma: a review of epidemiology and prognostic factors in Taiwan. <i>Eye</i> , 2021, 35, 1946-1953.	1.1	12
81	Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. <i>Annals of Hematology</i> , 2022, 101, 349-358.	0.8	12
82	Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis. <i>BMC Cancer</i> , 2013, 13, 107.	1.1	11
83	Ferucarbotran, a carboxydextran-coated superparamagnetic iron oxide nanoparticle, induces endosomal recycling, contributing to cellular and exosomal EGFR overexpression for cancer therapy. <i>RSC Advances</i> , 2015, 5, 89932-89939.	1.7	11
84	Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. <i>British Journal of Haematology</i> , 2019, 186, 72-85.	1.2	11
85	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study. <i>Blood</i> , 2019, 134, 1568-1568.	0.6	11
86	Airway Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Reverses Bronchopulmonary Dysplasia Superimposed with Acute Respiratory Distress Syndrome in an Infant. <i>Cell Medicine</i> , 2018, 10, 215517901875943.	5.0	10
87	Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 2144-2152.	0.8	9
88	Crystal-storing histiocytosis in a patient with ocular extranodal marginal zone lymphoma. <i>British Journal of Haematology</i> , 2013, 160, 419-419.	1.2	8
89	Complete response of myeloid sarcoma with cardiac involvement to radiotherapy. <i>Journal of Thoracic Disease</i> , 2016, 8, 1323-1328.	0.6	8
90	Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2018, 101, 28-37.	1.1	8

#	ARTICLE	IF	CITATIONS
91	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. <i>Bone Marrow Transplantation</i> , 2022, 57, 95-105.	1.3	8
92	Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. <i>PLoS ONE</i> , 2015, 10, e0137552.	1.1	7
93	Clinical Characteristics and Treatment Response of Hodgkin's Lymphoma in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 4-12.	0.8	6
94	Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever*. <i>Critical Care Medicine</i> , 2011, 39, 993-999.	0.4	6
95	Relapse of Acute Myeloid Leukemia at the Pituitary Gland: A Case Report and Review of Literature. <i>Endocrine Pathology</i> , 2012, 23, 172-176.	5.2	6
96	Clinical and Prognostic Implications of Roundabout 4 (Robo4) in Adult Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0119831.	1.1	6
97	CD9 Upregulation-Decreased CCL21 Secretion in Mesenchymal Stem Cells Reduces Cancer Cell Migration. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1738.	1.8	6
98	Pleural Effusion Heralds Acute Leukemic Transformation of Chronic Myelomonocytic Leukemia. <i>Southern Medical Journal</i> , 2008, 101, 1279-1280.	0.3	6
99	Quantitative Assessment of Minimal Residual Disease Predicts Outcome of Patients of Acute Myeloid Leukemia with Nucleophosmin (NPM) Mutation.. <i>Blood</i> , 2006, 108, 561-561.	0.6	6
100	Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. <i>Oncotarget</i> , 2017, 8, 81329-81342.	0.8	6
101	Granulomatous Slack Skin Presenting as Acquired Ichthyosis and Muscle Masses. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 29-32.	3.3	5
102	ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden. <i>Blood Cancer Journal</i> , 2020, 10, 99.	2.8	5
103	Validation of a <sc>Post-Transplant</sc> Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Database. <i>Oncologist</i> , 2021, 26, e2034-e2041.	1.9	5
104	Diffuse depigmentation in a patient with chronic myeloid leukemia. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 738-740.	0.6	4
105	Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2310-2315.	2.0	4
106	Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 293-302.	0.8	4
107	A Clinicopathological Study of Cytomegalovirus Lymphadenitis and Tonsillitis and Their Association with Epstein-Barr Virus. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2661-2675.	1.8	4
108	Outcomes of Different Haploidentical Transplantation Strategies from the Taiwan Blood and Marrow Transplantation Registry. <i>Cancers</i> , 2022, 14, 1097.	1.7	4

#	ARTICLE	IF	CITATIONS
109	Acquisition and Cure of Autoimmune Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of the Formosan Medical Association</i> , 2007, 106, 779-783.	0.8	3
110	Lung Abscess due to <i>Clostridium baratii</i> Infection in a Patient with Invasive Pulmonary Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 1153-1154.	1.8	3
111	Papillary Thyroid Cancer Associated With Light-Chain Amyloidosis Initially Presenting With Small-Bowel Bleeding and Protein-Losing Enteropathy. <i>Journal of Clinical Oncology</i> , 2010, 28, e557-e559.	0.8	3
112	Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1367-1373.	2.0	3
113	Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 471-480.	0.8	3
114	AML1/RUNX1 Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations.. <i>Blood</i> , 2009, 114, 1564-1564.	0.6	3
115	NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan. <i>International Journal of Hematology</i> , 2022, , 1.	0.7	3
116	Stem cell transplant for mantle cell lymphoma in Taiwan. <i>Scientific Reports</i> , 2022, 12, 5662.	1.6	3
117	Anaplastic Large Cell Lymphoma in Leukemic Transformation: Successful Treatment by Transplantation. <i>Journal of Clinical Oncology</i> , 2007, 25, 4490-4492.	0.8	2
118	HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 423-427.	0.8	2
119	Multiple Giant Mushroom-like Tumors Inside the Stomach. <i>Gastroenterology</i> , 2016, 151, e9-e10.	0.6	2
120	Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan. <i>International Journal of Hematology</i> , 2020, 112, 385-394.	0.7	2
121	Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study. <i>Cancer Reports</i> , 2021, , e1488.	0.6	2
122	Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. <i>Blood</i> , 2011, 118, 114-114.	0.6	2
123	Adult T cell leukemia/lymphoma presenting as multiple necrotic ulcers. <i>Dermatologica Sinica</i> , 2017, 35, 157-158.	0.2	1
124	Low-dose splenic irradiation is an alternative therapy for symptomatic splenomegaly in patients with myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1037-1040.	0.8	1
125	Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients. <i>Journal of the Formosan Medical Association</i> , 2021, 121, 643-643.	0.8	1
126	Clinical and Biological Characterization of Adult Patients with Acute Myeloid Leukemia Bearing T(7;11)(p15;p15) Analysis of 536 Patients. <i>Blood</i> , 2008, 112, 2535-2535.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Demographics and Long-Term Outcome of Incident Immune Thrombocytopenic Purpura: A Twelve-Years Nationwide Population-Based Study in Taiwan. <i>Blood</i> , 2015, 126, 3259-3259.	0.6	1
128	Incidence and predictors of idiopathic pneumonia syndrome in hematopoietic stem cell transplant patients: a nationwide registry study. <i>International Journal of Hematology</i> , 0, , .	0.7	1
129	Gene Mutations, Their Interactions and Associations with Immunophenotypes of Leukemia Cells in Patients with Primary Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 4138-4138.	0.6	0
130	Role of Gene Mutations in Adult Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 3373-3373.	0.6	0
131	Clinical Relevance of Pre- and Post-Transplantation Residual Disease, Hematogones and Natural Killer Cells in Adult Patients with Acute Leukemia. <i>Blood</i> , 2011, 118, 4490-4490.	0.6	0
132	Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4956-4956.	0.6	0
133	Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 49-49.	0.6	0
134	The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2705-2705.	0.6	0
135	Next-Generation Sequencing Minimal Residual Disease of Mantle Cell Lymphoma in Autologous Stem Cell Grafts and Its Implication on Tumor Recurrence. <i>Blood</i> , 2020, 136, 22-23.	0.6	0